Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 25;8(4):101153.
doi: 10.1016/j.adro.2022.101153. eCollection 2023 Jul-Aug.

Identification of Induced Radionuclides Produced from Dental Metals in Proton Beam Therapy for Head and Neck Cancer

Ryohei Kato  1 , Takahiro Kato  1   2 , Yuki Narita  1 , Sho Sasaki  1 , Kanako Takayama  3 , Masao Murakami  3
Affiliations

Identification of Induced Radionuclides Produced from Dental Metals in Proton Beam Therapy for Head and Neck Cancer

Ryohei Kato et al. Adv Radiat Oncol. .

Abstract

Purpose: To identify the induced radionuclides produced from dental metals in proton beam therapy and investigate the accuracy of the Monte Carlo (MC) simulation by comparing the measured radioactivity.

Methods and materials: Two dental metals of pure titanium and gold-silver-palladium alloy, commonly used in Japan, were used in this study. The dental metal placed at the center of Spread-out Bragg Peak was irradiated by 150-MeV passive scattering proton beam. The gamma rays emitted from the activated dental metals were measured using a high purity germanium (HPGe) detector. The induced radionuclides were identified from the measured gamma-ray energies. Furthermore, the Particle and Heavy Ion Transport code System v.3.24 and DCHAIN were used for the MC simulation. The measured radionuclides and their radioactivity were compared with the simulation results.

Results: In the MC simulation for the activated titanium, vanadium-47, with a half-life of 32.6 minutes had the strongest radioactivity among the induced radionuclides. The energy peaks of gamma rays emitted from titanium-51, scandium-43, scandium-44, and annihilation gamma rays were observed for the activated titanium in the HPGe detector. In the MC simulation for the activated gold-silver-palladium alloy, silver-108, with a half-life of 2.4 minutes had the strongest radioactivity. The energy peaks of gamma rays emitted from silver-104, silver-104 m, silver-108, and annihilation gamma rays were observed for the activated gold-silver-palladium alloy in the HPGe detector. Furthermore, the induced radionuclides and their radioactivity in the MC simulation were consistent with the measurement results for both dental metals, except for a few radionuclides.

Conclusions: We identify the induced radionuclides produced from 2 dental metals and compared their radioactivity between the measurements and the MC simulation. Although the identification of the induced radionuclides using the MC simulation remains uncertain, the MC simulation can be clinically effective for pre-estimating the induced radionuclides in proton beam therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gamma-ray spectra of the activated titanium measured by the high purity germanium detector after 2.5 minutes of the irradiation. Arrows showed radionuclides predicted by the Monte Carlo simulation (listed in Table 1). Abbreviation: BG = background.
Figure 2
Figure 2
Gamma-ray spectra of the activated gold-silver-palladium alloy measured by the high purity germanium detector after 2.5 minutes of the irradiation. Arrows showed radionuclides predicted by the Monte Carlo simulation (listed in Table 2). Abbreviation: BG = background.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • In Reply to Bäcker et al.
    Kato R, Kato T, Narita Y, Sasaki S, Takayama K, Murakami M. Kato R, et al. Adv Radiat Oncol. 2023 Nov 15;8(6):101365. doi: 10.1016/j.adro.2023.101365. eCollection 2023 Nov-Dec. Adv Radiat Oncol. 2023. PMID: 38047231 Free PMC article. No abstract available.
  • In Regard to Kato et al.
    Bäcker CM, Bäumer C, Kröninger K, Wulff J, Timmermann B. Bäcker CM, et al. Adv Radiat Oncol. 2023 Nov 15;8(6):101366. doi: 10.1016/j.adro.2023.101366. eCollection 2023 Nov-Dec. Adv Radiat Oncol. 2023. PMID: 38047215 Free PMC article. No abstract available.

References

    1. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy – A systematic review of clinical effectiveness. Radiother Oncol. 2007;83:123–132. - PubMed
    1. Mohan R, Grosshans D. Proton therapy – Present and future. Adv Drug Deliv Rev. 2017;109:26–44. - PMC - PubMed
    1. Blanchard P, Gunn GB, Lin A, Foote RL, Lee NY, Frank SJ. Proton therapy for head and neck cancers. Semin Radiat Oncol. 2018;28:53–63. - PubMed
    1. Newhauser WD, Koch NC, Fontenot JD, et al. Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy. Phys Med Biol. 2007;52:3979–3990. - PubMed
    1. Newhauser W, Fontenot J, Koch N, et al. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol. 2007;52:2937–2952. - PubMed

LinkOut - more resources